Keros Therapeutics, Inc. (KROS) stock has reached a 52-week low, trading at $15.67, marking a significant downturn for the biotechnology company. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 19.03, while technical indicators suggest the stock is in oversold territory. Over the past year, Keros Therapeutics has seen its stock value decrease by 60.16%, reflecting investor concerns and a challenging market environment for the sector. The company, which focuses on developing treatments for hematological and musculoskeletal disorders, has faced headwinds that have impacted its stock performance, leading to this new low. Investors are closely monitoring Keros's pipeline updates and market strategies as they assess the company's potential for recovery and growth amidst the current biotech landscape. Notably, analyst price targets range from $23 to $76, suggesting potential upside, with four analysts recently revising their earnings expectations upward. Discover more valuable insights and 13 additional ProTips for KROS on InvestingPro.
In other recent news, Keros Therapeutics has seen significant adjustments in its stock ratings and price targets following developments in its clinical trials. Truist Securities reduced its price target to $43.00 from the previous $100.00, maintaining a Buy rating. This decision was influenced by recent developments such as the company's collaboration with Takeda Pharmaceutical (TADAWUL:2070) Company (NYSE:TAK) and the potential of over $2 billion in opportunities for elirtecpt, a treatment for anemia. However, uncertainties around pulmonary arterial hypertension (PAH) treatments and the potential value in KER-065, a product candidate with possible applications in rare diseases and obesity, were also considered.
Oppenheimer adjusted its price target for Keros Therapeutics to $63.00, down from the previous $102.00, maintaining an Outperform rating. This followed the company's announcement to cease dosing in the mid-to-high dose cohorts of its Phase 2 TROPOS study for the drug cibotercept.
H.C. Wainwright maintained a Buy rating but reduced the price target from $100.00 to $47.00. This decision followed the company's announcement that it had halted dosing in two arms of its Phase 2 TROPOS trial for the treatment of pulmonary arterial hypertension (PAH) with its drug cibotercept (KER-012).
Jefferies reduced the price target for Keros Therapeutics to $23.00 from the previous $113.00 but maintained a Buy rating. The decision was made after Keros Therapeutics decided to discontinue two higher doses of its drug candidate, cibotercept, in a Phase 2 trial for Pulmonary Arterial Hypertension (PAH) due to adverse events.
TD Cowen downgraded the biotechnology company's shares from Buy to Hold following Keros Therapeutics' announcement of a halt in dosing for certain arms of its clinical trial. These are recent developments that investors should consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.